Current research status and prospects of neoadjuvant therapy for gallbladder cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHANG Yajun ¹ ,  ZHANG Yuewei ²

1. Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qinghai University, Xining 810001, P. R. China;
2. Department of Hepatobiliary Interventional Radiology, Beijing Tsinghua Chang Gung Hospital, Beijing 102218, P. R. China;

Corresponding?author：

ZHANG Yuewei, Email: zhangyuewei1121@sina.com

Keywords：

gallbladder cancer; neoadjuvant therapy; immunotherapy; targeted therapy.

DOI：

10.7507/1007-9424.202509008

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the current research status of neoadjuvant therapy for gallbladder cancer and evaluate the application value of combined therapeutic strategies. Method Relevant domestic and international literature was retrieved, and clinical research data in recent years were systematically reviewed to analyze the efficacy and safety of different therapeutic regimens. Results Neoadjuvant therapy for gallbladder cancer including interventional therapy, interventional therapy combined with targeted therapy/immunotherapy, radiotherapy and chemotherapy, radiotherapy combined with targeted therapy/immunotherapy, chemotherapy combined with targeted therapy/immunotherapy, targeted therapy combined with immunotherapy. Neoadjuvant therapy not only improves the key curative effect such as objective response rate, progression-free survival, and overall survival, but also provides an effective alternative for patients who are intolerant to chemotherapy. However, most existing studies are small-sample retrospective analyses or single-arm trials with selection bias, lacking unified standards and large-sample evidence-based medical support. Conclusions Neoadjuvant therapy (especially combined strategies) can significantly improve the survival benefits of gallbladder cancer patients. Future multicenter and large sample clinical studies are needed to optimize therapeutic strategies, combined with artificial intelligence technology to promote diagnosis and treatment of gallbladder cancer.

Citation： ZHANG Yajun, ZHANG Yuewei. Current research status and prospects of neoadjuvant therapy for gallbladder cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2026, 33(4): 584-590. doi: 10.7507/1007-9424.202509008 Copy

1.
2.
3.
4.
5.	Laurenzi A, Brandi G, Greco F, et al. Can repeated surgical resection offer a chance of cure for recurrent cholangiocarcinoma? Langenbecks Arch Surg, 2023, 408(1): 102. doi: 10.1007/s00423-023-02839-y.
6.
7.
8.
9.
10.	Liu G, Zhu D, He Q, et al. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for managing arterioportal shunt in hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study. J Hepatocell Carcinoma, 2024, 11: 1415-1428.
11.
12.
13.
14.
15.	中華醫學會外科學分會膽道外科學組, 中國醫師協會外科醫師分會膽道外科專家工作組. 膽道惡性腫瘤轉化治療專家共識(2025), 中國普通外科雜志, 2025, 34(8), 1589-1602.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.	US Food and Drug Administration. FDA Approval of Imfinzi (durvalumab) for Adult Patients with Locally Advanced or Metastatic Biliary Tract Cancer. (2022-09-02)[2026-02-05]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-locally-advanced-or-metastatic-biliary-tract-cancer.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.	Ni SJ, Wang X, Yuan L, et al. Claudin18.2 expression in gallbladder cancer correlates with immune activation and a favourable prognosis. J Clin Pathol, 2025, jcp-2024p-209914p. doi: 10.1136/jcp-2024-209914.
43.
44.
45.	Mayr C, Kiesslich T, Modest DP, et al. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned? Expert Opin Investig Drugs, 2022, 31(2): 221-233.
46.
47.
48.
49.
50.
51.
52.
53.

1.
2.
3.
4.
5. Laurenzi A, Brandi G, Greco F, et al. Can repeated surgical resection offer a chance of cure for recurrent cholangiocarcinoma? Langenbecks Arch Surg, 2023, 408(1): 102. doi: 10.1007/s00423-023-02839-y.
6.
7.
8.
9.
10. Liu G, Zhu D, He Q, et al. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for managing arterioportal shunt in hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study. J Hepatocell Carcinoma, 2024, 11: 1415-1428.
11.
12.
13.
14.
15. 中華醫學會外科學分會膽道外科學組, 中國醫師協會外科醫師分會膽道外科專家工作組. 膽道惡性腫瘤轉化治療專家共識(2025), 中國普通外科雜志, 2025, 34(8), 1589-1602.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30. US Food and Drug Administration. FDA Approval of Imfinzi (durvalumab) for Adult Patients with Locally Advanced or Metastatic Biliary Tract Cancer. (2022-09-02)[2026-02-05]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-locally-advanced-or-metastatic-biliary-tract-cancer.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42. Ni SJ, Wang X, Yuan L, et al. Claudin18.2 expression in gallbladder cancer correlates with immune activation and a favourable prognosis. J Clin Pathol, 2025, jcp-2024p-209914p. doi: 10.1136/jcp-2024-209914.
43.
44.
45. Mayr C, Kiesslich T, Modest DP, et al. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned? Expert Opin Investig Drugs, 2022, 31(2): 221-233.
46.
47.
48.
49.
50.
51.
52.
53.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Current research status and prospects of neoadjuvant therapy for gallbladder cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content